PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
22.84%
Net income growth of 22.84% while Healthcare median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
7.12%
D&A growth of 7.12% while Healthcare median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
-26.57%
SBC declines yoy while Healthcare median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-21.66%
Working capital is shrinking yoy while Healthcare median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
AP shrinks yoy while Healthcare median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
161.21%
Growth of 161.21% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
200.00%
Growth of 200.00% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
22.87%
CFO growth of 22.87% while Healthcare median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-183.51%
CapEx declines yoy while Healthcare median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-183.51%
Reduced investing yoy while Healthcare median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
-107.12%
We reduce issuance yoy while Healthcare median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.